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Abstract: Intensive care patients often experience hyperglycemia, insulin resistance (low insulin 
sensitivity), and high endogenous glucose production due to their critical situation. STAR is a model-based 
glycemic control protocol that uses insulin sensitivity (SI) identified on hourly bases to define patient 
variability. The numerical calculation during the identification phase of SI may result in negative SI value, 
which is an indication of high insulin resistance or another pathological patient state. Negative values of 
SI are physiologically not possible and are prevented in the parameter identification phase by a non-
negative constraint. These cases, when SI is forced to take a non-negative value, potentially result in poor 
blood glucose (BG) fitting and signaling some model limitations like an estimated low EGP. 
Using clinical data of 717 patients from three independent ICUs (Malaysia, New Zealand, and Hungary), 
the time occurrence and durations of constrained SI situations are analyzed, and different practical 
scenarios were suggested to estimate and handle patient's EGP levels in clinical application. An EGP 
estimation method is used to estimate the most suitable EGP value based on model fitting. By setting 
different EGP higher limit values, the fitting error and remaining constrained SI values are also analyzed 
and assessed.   
Results show that 96% of these constrained SI situations happen within the first 96H, and 95% of it lasts 
for 3h. Results also confirm that using an EGP limit higher than 3.5 s shows no further improvement in 
terms of modeling accuracy. 
Based on results, the most practical scenario to handle these situations is to keep the increased EGP until 
four days of treatment passed; after that, if it happens again, we may set back EGP to the initial value after 
3h each time we increase it. 
Keywords: Blood glucose; Glycemic control; Intensive Control Insulin-Nutrition-Glucose; Insulin 
resistance; Insulin sensitivity; Endogenous glucose production. 

1. INTRODUCTION 
Critically ill Intensive care unit (ICU) Patients can develop 
acute insulin resistance manifesting as hyperglycemia which 
can be induced primarily by stress and linked to raising the rate 
of morbidity and mortality  (Krinsley 2003). Safe, effective 
and consistent glycaemic control results have proven difficult 
(Bagshaw, Bellomo et al. 2009, Signal, Le Compte et al. 
2012), often caused the lack of patient-specificity and 
consideration of patient variability. This outcome illustrates 
the need for model-based patient-specific glycaemic control 
solutions. 
The Stochastic TARgeted (STAR) protocol is a model-based 
Glycemic control (GC) protocol (Evans, Shaw et al. 2011, 
Evans, Le Compte et al. 2012), directly capturing and 
modeling patient-specific intra and inter potential variability. 
STAR is driven by a model-based insulin sensitivity (SI), a key 
parameter to assess patient state variability (Docherty, Chase 
et al. 2011, Docherty, Chase et al. 2012). SI identification 
constraints negative values to a low minimum value as 
negative values are non-physiological. In this case, the model 
prediction will be biased and the fitting error becomes 
significant, signaling some model limitations (Pretty 2012). 
This situation may happen because of the complexity and 
severity of critical illness, such as severe sepsis (McCowen, 
Malhotra et al. 2001, Pretty 2012). 
In prior work (Anane, Benyo et al. 2019) we assessed the 
assumption that one of the model key parameters, endogenous 
glucose production (EGP), which is set to a fixed cohort-based 
value, is too low to represent the real physiological value of 
certain patients. A constrained SI value is thus an indication 
that EGP needs to be raised to a higher value. Increasing EGP 
enabled the model to follow the observed BG dynamics and 
surpass this limitation, also showed impressive results in error 
reduction and change in the insulin sensitivity distribution. 
In this study, practical scenarios were suggested for the clinical 
implementation of an EGP estimation method by analyzing the 
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time occurrence and duration of these episodes, using clinical 
data of 717 patients from 3 different ICUs. 
2. METHODS 
2.1  ICING model 
STAR utilizes the Intensive Care Insulin-Nutrition-Glucose 
(ICING) model to simulate the fundamental metabolic 
dynamics of the glucose/insulin system of the human body. 
The main 3 of 7 total equations are defined: 




𝑃𝑃(𝑡𝑡) + 𝐸𝐸𝐺𝐺𝑃𝑃 − 𝐶𝐶𝐶𝐶𝑆𝑆
𝑉𝑉𝐺𝐺  
 (1) 
𝑆𝑆̇ = −𝑛𝑛𝑘𝑘𝑆𝑆(𝑡𝑡) − 𝑛𝑛𝐿𝐿
𝑆𝑆(𝑡𝑡)
1 + 𝑎𝑎𝐼𝐼𝑆𝑆(𝑡𝑡)
− 𝑛𝑛𝐼𝐼(𝑆𝑆(𝑡𝑡) − 𝑄𝑄(𝑡𝑡)) + 
𝑢𝑢𝑒𝑒𝑒𝑒(𝑡𝑡)
𝑉𝑉𝐼𝐼
+ (1 − 𝑥𝑥𝐿𝐿)
𝑢𝑢𝑒𝑒𝑒𝑒(𝐺𝐺)
𝑉𝑉𝐼𝐼
      (2) 
?̇?𝑄 = 𝑛𝑛𝐼𝐼(𝑆𝑆(𝑡𝑡) − 𝑄𝑄(𝑡𝑡)) − 𝑛𝑛𝐶𝐶
𝑄𝑄(𝑡𝑡)
1+𝑎𝑎𝐺𝐺𝑄𝑄(𝑡𝑡)
       (3) 





G Blood glucose  (mmol/liter) 
Q Interstitial insulin 
concentration 
(mU/liter) 






PG Insulin independent 
glucose removal  
0.006 (min−1) 
SI Insulin-mediated 
glucose removal  
(liter/mU/min) 




All equations, parameters, inputs, and variables are defined in 
(Stewart, Pretty et al. 2016). 
2.2 Patient data /cohorts 
Clinical data that contains a patient's personal information, 
blood glucose measurements, and insulin/nutrition treatment 
was collected from 3 different cohorts of 717 ICU patients.  
216 from the International Islamic University Malaysia 
Medical Centre, Malaysia, 408 from Christchurch Hospital, 
New Zeeland, 93 patients from Kalman Pandy Hospital, 
Gyula, Hungary. 
Patients with glycemic control of less than 10 hours were 
excluded. The 3 cohorts were treated with STAR. Malaysian 
patients were using a target range of 6.0-10.0 mmol/L with 
continuous insulin infusions. New Zealand patients had a 
lower BG target range 4.4-8.0 mmol/L and insulin delivered 
via bolus. Hungarian patients were treated with continuous 
insulin infusion to the lower range (Lin, Razak et al. 2011). 
2.3  Insulin sensitivity identification 
SI, as a single parameter, is used to represent the 'whole body' 
metabolic state condition, and it captures patient-specific 
deviation from model population parameters. 
Clinical data including two last BG measurements, 
insulin/nutrition inputs, and ICING model Equations (1)-(7) is 
utilized to identify SI in hourly bases using the integral-based 
method (Lin, Razak et al. 2011). 
The Identified SI is used for the prediction of the blood glucose 
outcomes based on current treatment suggestions.   
In the identification phase, Negative SI values are prevented 
and constrained to a minimum value = 1e-7. Negative values 
of SI are also an indication of insulin resistance but are 
physiologically not possible. 
2.4 Insulin resistance, constrained SI and low EGP 
Insulin sensitivity (SI), is uniquely identified from clinical data 
on an hourly basis. Patient variability is assessed by the hour-
to-hour change in SI levels. Low values of SI indicate insulin 
resistance and the need to either add insulin or reduce nutrition 
to achieve lower glycemic levels (Lin, Razak et al. 2011).  
Another key parameter is the endogenous glucose production 
(EGP) representing the net glucose produced by the body and 
released into the blood. It directly impacts SI by contributing 
to the net glucose flux to be balanced by insulin-mediated 
glucose uptake in equation (1) (McCowen, Malhotra et al. 
2001, Thorell, Rooyackers et al. 2004). In the STAR 
Treatment protocol, EGP is set to a cohort-based value of 1.16 
mmol/min. 
Cases, where SI is constrained to a non-negative value, are 
often preceded by an unexpected rise in blood glucose levels, 
potentially resulting in a poor BG fitting. One main cause is 
the assumed EGP value is too low to represent the real 
physiological value at that specific situation. These situations 
affect 22-62% of ICU patients from the 3 different cohorts. 
2.5  EGP estimation approach 
The model-based EGP estimation method developed in 
(Anane, Benyo et al. 2019) is used to adjust EGP levels based 
on patient-specific SI levels and runs only when the identified 
SI value hits the lower constraint limit (see fig. 1). The EGP 
parameter value range in this paper is 1.25<EGP<3.5 
mmol/min with a step of 0.25 selected experimentally which 
gives a vector of N=10 after the initial fixed value of EGP = 
1.16. The upper range limit value (3.5) selected based on 
results to be shown in the result section. 
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Fig. 1. Illustration of the implementation of the new EGP 
estimation method in the SI identification phase. 
2.6  Analysis 
In this paper, in order to provide practical scenarios of how we 
can handle these constrained SI situations, we analyzed the 
time occurrence and duration of these episodes for the three 
different ICUs. We analyzed and compared different EGP 
upper limit values and the number of remaining constrained SI 
values using a cohort of 22 most affected Malaysian patients. 
3. RESULTS 
3.1  Insulin resistance, constrained SI and low EGP 
Fig. 2 shows the distribution in time per day of constrained SI 
for the 3 different cohorts. The overall trends for the New 
Zealand and Malaysian cohorts are exponential with most 
episodes arising in the first 3-4 days, as expected given stress 
response physiology. The Hungarian cohort has quite a similar 
pattern except on the third day where there was a rise in the 




Fig. 2. Constrained SI probability of occurrence per day (1bin= 
24h) for MLS (top), NZ (middle) and HU (bottom). 
Overall results show ~30-60% of the occurrence situations 
happen in the first 24H (first day), ~46-80% of the occurrence 
situations happen in the first 48H, ~78-90% of the occurrence 
situations happen in the first 72H and ~90-96% of the 
occurrence situations happen in the first 96H across all 
cohorts. Less than 10% of constrained SI occurrence occurs 
after the 4th day. 
3.2  Duration of episodes 
Fig. 3 shows the time duration in hours of constrained SI for 
the 3 different cohorts. All 3 cohorts have similar exponential 
trends with most episodes lasting up to 4 hours. 
A small minority of New Zeeland patients have constrained SI 
duration up to 18 hours, where in Hungarian and Malaysian 
patients, the maximum is 7-8 hours. 
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Fig. 3. Duration of constrained SI episodes when it occurs 
(1bin= 1hour) for MLS (top), NZ (middle) and HU (bottom). 
Overall results show ~53-71% of the insulin resistance 
situations last for 1 hour, ~19-27% of the insulin resistance 
situations last for 2 hours and ~5-11% of the insulin resistance 
situations last for 3 hours. Thus ~89-95% of the insulin 
resistance situations last between 1-3 hours across all the 
cohorts. 
3.3  EGP parameter value limits, fitting error and remaining 
constrained SI values 
Out of 216 Malaysian patients (the most affected cohort), we 
selected patients with the poorest BG fitting (BG error > 20%) 
to analyze the effect of applying different EGP upper limits 
mainly on modeling error (the result of the selecting is 22 
patients). Table 2 shows Mean/Max fitting error and remaining 
constrained SI hours after increasing EGP with different limits 
compared to using a fixed EGP (1.16 mmol/min). 
Table 2.  MEDIAN IQR OF ERROR PER COHORT AND MEDIAN IQR 
OF MAXIMUM ERROR PER PATIENT. 
 
EGP(mmol/min) 1.16 2.5 
Mean/Max Mean Max Mean Max 
Fitting Error (%) 18 48 2.03 16.89 
N° of remaining 
constrained SI 
468 18  
 
3 3.5 6 
Mean Max Mean Max Mean Max 
1.04 6.38 0.77 2.33 0.63 2.23 
9  6  3  
 
Using fixed EGP values comes with significant fitting error 
and a large number of constrained SI hours. Increasing the 
limit of EGP to 2.5 mmol/min shows a reduction of 96% in the 
constrained SI value, but still, have a slightly large maximum 
fitting error. In contrast, setting the limit of EGP up to 3.5 
mmol/min shows a large reduction in BG fitting error to a very 
low value (2.33%) and reduction of constrained SI values by 
98%. Using EGP values higher than 3.5 mmol/min did not 
show any further improvement and using 6 mmol/min as a 
limit has similar results to using 3.5 mmol/min. 
Forcing SI to take a non-negative value is a model limitation, 
and the identified constrained SI will result in a poor SI 
prediction in the real clinical application, which also will result 
in a poor BG prediction. 
In the method presented in the paper, there is a situation where 
the EGP values minimizing the BG fitting error results in also 
a constrained SI value (see Table 3). This leads to the idea of 
modifying the estimation method to prioritize the positive SI 
values over a constrained value with the acceptance of a small 
BG fitting error. 
Table 3.  THE NUMBER OF REMAINING CONSTRAINED SI IN ALL THE 
COHORTS USING FIX EGP VS. ESTIMATED EGP (EST EGP) 
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Results show over 98% of the constrained SI disappears when 
estimating EGP up to 3.5 mmol/min. This means no need for 
any further modifications of the current estimation method. 
4. DISCUSSION 
4.1  Insulin resistance and patient's condition relationship 
For those hours where SI was hitting the lower limit, 90-96% 
of them occurred in the first 96 hours of stay for the Malaysian, 
New Zealand and Hungarian patients, as shown in Fig. 2. This 
early occurrence is likely due to the surge in EGP seen 
particularly in severe sepsis and septic shock patients in the 
first 12-24 hours of the stay (Shaw, G.M. 2012, Chase, J.G. 
2012). Thus, the location of these hours qualitatively matches 
broad clinical expectations, where severe sepsis is one of the 
leading causes of ICU admission (McCowen, Malhotra et al. 
2001, Pretty 2012). 
Around 50% of the constrained SI situation happens in the first 
24H for Malaysian and New Zealand patients where only 30% 
for the Hungarian cohort with the highest rate was on the third 
day of the ICU stay. These differences may also reflect cohort 
differences in the incidence of greater complexity and level of 
critical illness, such as incidence of severe sepsis, in some 
cohorts, which can occur from the areas and types of patients 
treated, as well as from treatment selection or failure bias. 
4.2  Handling EGP and constrained SI 
Using a limit higher than 3.5 mmol/min shows no further 
improvement and for that, there will be no reason to go above 
that. The 3.5 mmol/min limit of EGP still an acceptable 
physiological value for a patient with a very high EGP. 
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particularly in severe sepsis and septic shock patients in the 
first 12-24 hours of the stay (Shaw, G.M. 2012, Chase, J.G. 
2012). Thus, the location of these hours qualitatively matches 
broad clinical expectations, where severe sepsis is one of the 
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critical illness, such as incidence of severe sepsis, in some 
cohorts, which can occur from the areas and types of patients 
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that. The 3.5 mmol/min limit of EGP still an acceptable 
physiological value for a patient with a very high EGP. 
 
 
     
 
The question now is, what should we do after we increase 
EGP? And For how long should we keep it high? 
Based on the results achieved, we suggest different practical 
scenarios to handle EGP and the identified constrained SI in 
the clinical application: 
1) Set back EGP to the initial value after 72H-96 of treatment: 
As ~78-96% of the occurrence situations happen in the first 
72-96H, this scenario tends to be the most preferable, because 
once we identify a patient with an insulin resistance 
(constrained SI) it is more likely to happen more frequently 
and it will continue until the 4th day where up to 96% of the 
situations happens within. 
2) Set back EGP to the initial value after 3-4H from increasing 
it: As ~90-95% of the cases last between 1 and 3 hours, it is 
possible to set back the estimated EGP to the initial value, 
which is 1.16 once 3 hours passed. However, the downside of 
this scenario that random frequent occurrence of the 
constrained SI may lead to an 'increase–set_back–
increase_again' loop, also we will be always missing the first 
occurrence as the identification stats right after having the new 
BG measurements.     
3) Keep EGP high for the entire treatment period: We assume 
once we identify a patient with a constrained SI it is more 
likely that it will happen again, and this patient will have a high 
EGP level during the entire stay in the ICU, the downside of 
this choice is we may overestimate the EGP level especially 
after patient state stabilize. 
The more practical way to handle EGP estimation is to use a 
mix of approaches 1 and 2: 
If the constrained SI happens in the first days of treatment, we 
keep the increased EGP value until the 4th day of stay. If it 
happens after the 4th day, we set back the initial EGP values 
after 3 hours of each time we increase it. 
The first reason behind this choice is that we know patients 
have a higher EGP in their first days after ICU admission, so 
we want to increase our estimation only for those four first 
days. After that period, if we keep our high estimated value, 
we may end up overestimating the EGP level. The second 
reason is that after the first four days, a patient may have some 
spikes in EGP as we saw in Fig. 2, so increasing and keeping 
it four 3 to 4 hours before setting back to initial value seems to 
be also a good solution. 
7. CONCLUSIONS 
Understanding the relationship between hyperglycemia, 
insulin resistance, and high endogenous glucose production 
has a huge impact on model-based control and treatment in 
intensive care units. Underestimating the EGP in situations 
where patients are experiencing insulin resistance showed 
poor modelling results. By the estimation of the right EGP 
level, it significantly improves the outcomes and surpasses the 
model limitation. The next step is to design a practical way of 
implementing the new EGP estimation method on the STAR 
clinical application. Based on results, 96% of these constrained 
SI episodes happen within the first 96H and 95% of it lasts for 
3h, for this the most practical scenario to handle these 
situations is to keep the increased EGP until 4 days of 
treatment passed, after that if it happens again we may set back 
EGP to the initial value after 3h each time we increase it. In 
summary, the clinical implementation of the EGP estimation 
method presented can effectively capture and handle patients' 
EGP variability, improve the model outcomes, enhance 
glycemic control and create a space for further development. 
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